Fig. 3From: Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE studyPeriprocedural-edoxaban interruption over time. Major surgeries were considered high risk based on EHRA bleeding risk levels. Nonmajor surgeries were assigned risk levels per EHRA procedural bleeding risk criteria. EHRA, European Heart Rhythm Association Back to article page